See more : SCGJWD Logistics Public Company Limited (SJWD.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Kyverna Therapeutics, Inc. (KYTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kyverna Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Surge Energy Inc. (SGY.TO) Income Statement Analysis – Financial Results
- Alinma Hospitality REIT Fund (4349.SR) Income Statement Analysis – Financial Results
- Rottneros AB (publ) (RTERF) Income Statement Analysis – Financial Results
- Anpec Electronics Corporation (6138.TWO) Income Statement Analysis – Financial Results
- AEM Holdings Ltd. (AWX.SI) Income Statement Analysis – Financial Results
Kyverna Therapeutics, Inc. (KYTX)
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 7.03M | 5.66M |
| Cost of Revenue | 1.71M | 1.05M | 586.00K |
| Gross Profit | -1.71M | 5.97M | 5.07M |
| Gross Profit Ratio | 0.00% | 85.04% | 89.64% |
| Research & Development | 49.92M | 28.40M | 25.85M |
| General & Administrative | 12.48M | 8.01M | 6.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 12.48M | 8.01M | 6.15M |
| Other Expenses | 0.00 | -9.00K | -2.00K |
| Operating Expenses | 62.41M | 36.41M | 32.00M |
| Cost & Expenses | 62.41M | 36.41M | 32.00M |
| Interest Income | 2.28M | 565.00K | 1.00K |
| Interest Expense | 187.00K | 65.00K | 3.00K |
| Depreciation & Amortization | 1.71M | 1.05M | 586.00K |
| EBITDA | -58.47M | -27.78M | -25.76M |
| EBITDA Ratio | 0.00% | -395.40% | -455.46% |
| Operating Income | -62.41M | -29.38M | -26.35M |
| Operating Income Ratio | 0.00% | -418.28% | -465.81% |
| Total Other Income/Expenses | 2.04M | 491.00K | -4.00K |
| Income Before Tax | -60.37M | -28.89M | -26.35M |
| Income Before Tax Ratio | 0.00% | -411.29% | -465.88% |
| Income Tax Expense | 0.00 | 56.00K | 1.00K |
| Net Income | -60.37M | -28.89M | -26.35M |
| Net Income Ratio | 0.00% | -411.29% | -465.88% |
| EPS | 0.00 | -1.12 | -1.02 |
| EPS Diluted | 0.00 | -1.12 | -1.02 |
| Weighted Avg Shares Out | 673.62M | 25.80M | 25.80M |
| Weighted Avg Shares Out (Dil) | 673.62M | 25.80M | 25.80M |
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Investors Should Join The Inquiry
Kyverna Therapeutics Inc. May Have Violated Securities Regulations And The Schall Law Firm Wants Stakeholders With Losses To Reach Out
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Impacted Investors Are Urged To Play A Part
Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says
Kyverna Therapeutics Inc. May Be Liable To Compensate Investors And Those With Losses Should Contact The Schall Law Firm About An Inquiry
The Schall Law Firm Wants The Public's Contributions To An Investigation Into Whether Kyverna Therapeutics Inc Committed Securities Fraud
Kyverna Therapeutics Inc. Is Being Looked Into For Committing Securities Law Infractions And Stakeholders Are Invited To Help The Schall Law Firm
A Securities Fraud Inquiry Has Been Launched Into Kyverna Therapeutics Inc And The Schall Law Firm Is Seeking Investor Participation
The Schall Law Firm Is Investigating Whether Kyverna Therapeutics Inc. Violated Securities Laws And Shareholders Are Urged To Reach Out
Investors In Kyverna Therapeutics Inc Are Encouraged To Assist The Schall Law Firm In A Securities Fraud Inquiry
Source: https://incomestatements.info
Category: Stock Reports